0
0
Biological E Limited, a leading Indian vaccine manufacturer, has announced plans to produce the HPV9 vaccine for distribution in India, as well as for global health organizations UNICEF and the Pan American Health Organization (PAHO). This move is aimed at expanding access to the human papillomavirus (HPV) vaccine, which plays a crucial role in preventing cervical cancer and other HPV-related diseases.
The HPV9 vaccine, also known as a nonavalent vaccine, protects against nine strains of the human papillomavirus, offering broader protection compared to earlier versions. By manufacturing this vaccine domestically, Biological E is expected to strengthen India’s immunization efforts and support international public health initiatives through UNICEF and PAHO tender markets.
This development aligns with global efforts to increase HPV vaccination coverage, particularly in low- and middle-income countries where cervical cancer remains a significant public health challenge. The partnership is anticipated to improve vaccine availability and affordability, contributing to the World Health Organization’s goal of eliminating cervical cancer as a public health problem.
Disclaimer: This news article is based on information available as of July 2, 2025, and is intended for informational purposes only. For the most current details and official statements, please refer to announcements from Biological E, UNICEF, PAHO, and relevant health authorities1.
